New U.S. biodefense agency signed into law

BARDA aims to facilitate product development by filling the funding gap between testing and commercialization

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
Last month, U.S. President George Bush signed into law the US Biodefense Advanced Research and Development Authority (BARDA), designed to speed up the development of biodefense countermeasures by funding products in the so-called advanced development stage, between the end of initial testing and commercial manufacture. However, many details about how the new entity will operate -- and its potential effect on existing drug research and development -- have not yet been entirely settled. BARDA, a program of the Department of Health and Human Services (HHS), is intended to reinvigorate Project Bioshield, the HHS agency created in July 2004 to stockpile anti-bioterror drugs and vaccines. Project Bioshield has been criticized by large pharmaceutical companies who claim its provisions make biodefense manufacturing too risky and not profitable enough, while smaller companies interested in bioterror research say they have lacked the financial backing to develop these products.One example of a company that might have been helped by BARDA is VaxGen, the small California biotech whose $877.5 million contract to create a new anthrax vaccine was cancelled by HHS in December because its vaccine broke down too quickly to survive long storage. VaxGen, a small biotech with limited funds, could not afford to try a different formulation; under BARDA, VaxGen might have been eligible for periodic payments to find a solution. It is not yet clear how BARDA will distribute its anticipated funding ($1.07 billion through fiscal year 2008). Although Senator Richard Burr (R-NC), the legislation's Senate sponsor, has said that BARDA will act as an "aggressive venture capitalist," HHS spokesman Bill Hall told The Scientist the BARDA legislation doesn't give his agency the authority "to start infusing cash into organizations in a fashion akin to ?venture capitalists,'" who typically invest money in return for partial ownership in companies.Sen. Burr has also suggested that BARDA could fund universities and research institutions to do advanced development -- in effect, to become drug manufacturers themselves. Although this novel opportunity could point to more profits for universities, it might also spell trouble, according to some experts. Anthony Sinskey, co-director of the Program on the Pharmaceutical Industry at the Massachusetts Institute of Technology Sloan School of Management, said, "University people can't do [manufacturing] well. They think they can but they can't." Mani Subramanian, who is overseeing the construction of a small biologics manufacturing plant at the University of Iowa, agreed. "The university is not a good place to develop large-scale process and manufacturing."The BARDA legislation was designed so there would be little overlap with the National Institutes of Health -- NIH will handle basic research, and BARDA will develop and manufacture the drugs. "So I really look at it very much so as a complimentary thing, not that they're going to be encroaching on our turf at all," said Tony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).Since September 11, 2001, NIAID has been in charge of deciding what basic bioterror research the nation will fund. According to a spokesperson for Sen. Burr, NIAID will keep that role, and the BARDA director will be "much more of a requirements-driven person," creating products public health officials want. So could there someday be a conflict, with BARDA disagreeing with NIAID about which research to fund? "I would imagine that that may happen," she said. "But what I'm not saying is that NIH is going to completely change their course of business." NIH will still make the final decisions, she said.Diane Griffin, president of the American Society for Microbiology, agreed the new agency likely won't butt heads with NIH. "I don't think people are too concerned that that this is going to happen," she told The Scientist. John Dudley Miller jmiller@the-scientist.com Links within this articleT. Agres, "US weighs biodefense measures," The Scientist, November 2, 2005 http://www.the-scientist.com/article/display/22818/T. Agres, "Companies on the fence about biodefense," The Scientist, October 25, 2004 http://www.the-scientist.com/2004/10/25/56/1/J.D. Miller, "US cancels anthrax vaccine contract," The Scientist, December 21, 2006. http://www.the-scientist.com/news/display/38331Senator Richard Burr Press Release, "Senate Passes Burr's Bipartisan Biodefense and Pandemic Preparedness Legislation," December 5, 2006. http://www.burr.senate.gov/index.cfm?FuseAction=PressReleases.Detail&PressRelease_id=262&Month=12&Year=2006
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • John Dudley Miller

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide